This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for BeneFIX® (nonacog alfa) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

BeneFIX has a favourable safety profile

Safety profile 

​​​The most common adverse reactions reported in clinical trials of previously treated patients (PTPs) and identified in post-marketing use were1:

  • Headache, cough, pyrexia – very common (≥10%)

  • Hypersensitivity, dizziness, dysgeusia, phlebitis, flushing, vomiting, nausea, rash, urticaria, chest discomfort, infusion-site reaction, infusion-site pain – common (≥1% to <10%)

Low inhibitor formation

Data from more than 11,000 infusions of BeneFIX demonstrate that inhibitor development and allergic reactions were low 2,3:

  • Results of pooled safety data from 6 prospective studies showed that 1.2% of patients developed inhibitors on BeneFIX (5/412)2
    • 4 of these patients also exhibited an allergic-type manifestation
  • Results from a retrospective study suggest that there is no difference in the frequency of allergic reactions or inhibitor development in patients receiving BeneFIX versus those receiving plasma-derived factor IX concentrates3

Explore more

Find out about the BeneFIX efficacy

Click here

Find out about BeneFIX dosing

Click here

  1. BeneFIX (nonacog alfa) Summary of Product Characteristics:
  2. Rendo P et al. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis 2015;26(8):912–918.
  3. Recht M et al. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011;17(3):494–499.
PP-BEN-GBR-0391. March 2021

Contact Pfizer

Speak to a member of the Pfizer haemophilia team.

Click here

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020